Skip to content
You are now leaving https://www.ionispharma.com to visit

New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi

29% Objective Response Rate and 57% Disease Control Rate in Combination with Immune Checkpoint Inhibitor Treatment in Patients with Head and Neck Cancer Four Complete Responses and Four Partial Responses Observed in 28-patient Study CARLSBAD, Calif. , Sept.